DeMets Lecture Series with Dr. Michael Proschan, NIAID
Subgroup Mortality Results for Remdesivir in COVID-19: Real or the Play of Chance?
Event Details
Date
Thursday, November 3, 2022
Time
3:30-4:45 p.m.
Location
Description
This lecture is for a general clinical trials and public health audience.
Dr. Proschan's talk describes the Adaptive COVID-19 Treatment Trial (ACTT-1), the first randomized controlled trial showing a beneficial effect of a treatment for COVID-19. Experimental subjects who received remdesivir plus standard care fared better than controls, and supplemental oxygen seems to have a striking effect on patient recovery. Is this real? If real, does it reflect overall mortality or a subgroup effect?
Dr. Proschan's talk describes the Adaptive COVID-19 Treatment Trial (ACTT-1), the first randomized controlled trial showing a beneficial effect of a treatment for COVID-19. Experimental subjects who received remdesivir plus standard care fared better than controls, and supplemental oxygen seems to have a striking effect on patient recovery. Is this real? If real, does it reflect overall mortality or a subgroup effect?
Cost
Free
Contact